{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:05:06Z","timestamp":1787601906108,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Cachexia is defined as ongoing loss of skeletal muscle mass, with or without depletion of adipose tissue and is a common syndrome in cancer patients, affecting 50% of those diagnosed. Cachexia, which cannot be fully reversed and causes significant functional impairment is caused by various mechanisms such as an altered energy balance and disruption of homeostatic control by the central nervous system. This central nervous system deregulation involves hypothalamic pituitary adrenal (HPA) axis stimulation, which can be triggered by IL-1R1 engagement on neuronal processes and endothelium in the microvasculature of the hypothalamus. This review will explore current evidence regarding both the importance of IL-1\u03b1 in the various components of cancer cachexia and its potential as a therapeutic target.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>IL-1\u03b1, which signals through IL-1R1, has been identified as a key agonist in the IL-1 pathway. As such, IL-1\u03b1 has been explored as a therapeutic target in cancer cachexia, leading to the development of bermekimab, a mAb which neutralizes IL-1\u03b1. With a limited array of medication currently available to treat cancer cachexia, bermekimab represents a possible therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>IL-1\u03b1 is a key mediator in cachexia development and targeting this may be a viable therapeutic target.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000398","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T12:21:24Z","timestamp":1539087684000},"page":"453-459","source":"Crossref","is-referenced-by-count":33,"title":["Targeting IL-1\u03b1 in cancer cachexia: a narrative review"],"prefix":"10.1097","volume":"12","author":[{"given":"James J.","family":"McDonald","sequence":"first","affiliation":[{"name":"Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"McMillan","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, University of Glasgow, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.A.","family":"Laird","sequence":"additional","affiliation":[{"name":"Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh"},{"name":"St Columba's Hospice, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230926","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R2-20230926","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jcsm.12107","article-title":"Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients","volume":"7","author":"Rutten","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R3-20230926","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","article-title":"Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer","volume":"34","author":"Blauwhoff-Buskermolen","year":"2016","journal-title":"J Clin Oncol"},{"key":"R4-20230926","doi-asserted-by":"crossref","first-page":"e000097","DOI":"10.1136\/bmjgast-2016-000097","article-title":"Cachexia in cancer: what is in the definition?","volume":"3","author":"Vanhoutte","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"R5-20230926","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ctrv.2013.11.007","article-title":"Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score","volume":"40","author":"Douglas","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"R6-20230926","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","article-title":"ESPEN expert group recommendations for action against cancer-related malnutrition","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"R7-20230926","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jpainsymman.2016.12.330","article-title":"Prognostic tools in patients with advanced cancer: a systematic review","volume":"53","author":"Simmons","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"R8-20230926","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.2015.65.7742","article-title":"Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response","volume":"34","author":"Laird","year":"2016","journal-title":"J Clin Oncol"},{"key":"R9-20230926","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2015.03.015","article-title":"Inflammation induced loss of skeletal muscle","volume":"80","author":"Londhe","year":"2015","journal-title":"Bone"},{"issue":"(11 Pt 2)","key":"R10-20230926","first-page":"4138","article-title":"Role of prostaglandins in the production of hypercalcemia by tumors","volume":"38","author":"Tashjian","year":"1978","journal-title":"Cancer Res"},{"key":"R11-20230926","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R12-20230926","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R13-20230926","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imr.12614","article-title":"IL-1 and IL-1 regulatory pathways in cancer progression and therapy","volume":"281","author":"Mantovani","year":"2018","journal-title":"Immunol Rev"},{"key":"R14-20230926","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/ajcn.70.2.183","article-title":"Geriatric cachexia: the role of cytokines","volume":"70","author":"Yeh","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"R15-20230926","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0899-9007(96)00164-5","article-title":"Cracking the riddle of cancer anorexia","volume":"12","author":"Laviano","year":"1996","journal-title":"Nutrition"},{"key":"R16-20230926","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1210\/en.2009-1135","article-title":"Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130","volume":"151","author":"Grossberg","year":"2010","journal-title":"Endocrinology"},{"key":"R17-20230926","first-page":"1432","article-title":"Role of the central melanocortin system in cachexia","volume":"61","author":"Marks","year":"2001","journal-title":"Cancer Res"},{"key":"R18-20230926","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1210\/en.2007-0017","article-title":"Regulation of central melanocortin signaling by interleukin-1 beta","volume":"148","author":"Scarlett","year":"2007","journal-title":"Endocrinology"},{"key":"R19-20230926","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1210\/en.2007-1680","article-title":"Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation","volume":"149","author":"Scarlett","year":"2008","journal-title":"Endocrinology"},{"key":"R20-20230926","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1210\/en.2002-221099","article-title":"Differential role of melanocortin receptor subtypes in cachexia","volume":"144","author":"Marks","year":"2003","journal-title":"Endocrinology"},{"key":"R21-20230926","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1523\/JNEUROSCI.14-02-00897.1994","article-title":"A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons","volume":"14","author":"Ericsson","year":"1994","journal-title":"J Neurosci"},{"key":"R22-20230926","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1084\/jem.20111020","article-title":"Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic\u2013pituitary\u2013adrenal axis","volume":"208","author":"Braun","year":"2011","journal-title":"J Exp Med"},{"key":"R23-20230926","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/S0002-9440(10)63608-5","article-title":"Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer","volume":"163","author":"Kumar","year":"2003","journal-title":"Am J Pathol"},{"key":"R24-20230926","doi-asserted-by":"crossref","first-page":"C706","DOI":"10.1152\/ajpcell.00626.2008","article-title":"Interleukin-1 stimulates catabolism in C2C12 myotubes","volume":"297","author":"Li","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"R25-20230926","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am J Med"},{"key":"R26-20230926","doi-asserted-by":"crossref","first-page":"10476","DOI":"10.1523\/JNEUROSCI.3357-07.2007","article-title":"Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration","volume":"27","author":"Ching","year":"2007","journal-title":"J Neurosci"},{"key":"R27-20230926","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.4049\/jimmunol.170.11.5697","article-title":"IL-1 alpha, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis","volume":"170","author":"Murphy","year":"2003","journal-title":"J Immunol"},{"key":"R28-20230926","first-page":"437","article-title":"Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo","volume":"16","author":"McKenzie","year":"1996","journal-title":"Anticancer Res"},{"key":"R29-20230926","first-page":"5051","article-title":"Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma\/nude mouse system","volume":"53","author":"Chirivi","year":"1993","journal-title":"Cancer Res"},{"key":"R30-20230926","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4251\/wjgo.v7.i4.17","article-title":"Cancer cachexia, mechanism and treatment","volume":"7","author":"Aoyagi","year":"2015","journal-title":"World J Gastrointest Oncol"},{"key":"R31-20230926","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol"},{"key":"R32-20230926","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/14712598.2017.1347631","article-title":"MABp1 for the treatment of colorectal cancer","volume":"17","author":"O'Sullivan Coyne","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"R33-20230926","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10637-015-0226-6","article-title":"Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in nonsmall cell lung cancer","volume":"33","author":"Hong","year":"2015","journal-title":"Invest New Drugs"},{"key":"R34-20230926","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201812000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T07:15:50Z","timestamp":1695712550000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201812000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000398","relation":{},"ISSN":["1751-4258","1751-4266"],"issn-type":[{"value":"1751-4258","type":"print"},{"value":"1751-4266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}